Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium

TY - JOUR

T1 - Use of common analgesic medications and ovarian cancer survival

T2 - results from a pooled analysis in the Ovarian Cancer Association Consortium

AU - Dixon, Suzanne C

AU - Nagle, Christina M

AU - Wentzensen, Nicolas

AU - Trabert, Britton

AU - Beeghly-Fadiel, Alicia

AU - Schildkraut, Joellen M

AU - Moysich, Kirsten B

AU - deFazio, Anna

AU - Risch, Harvey A

AU - Rossing, Mary Anne

AU - Doherty, Jennifer A

AU - Wicklund, Kristine G

AU - Goodman, Marc T

AU - Modugno, Francesmary

AU - Ness, Roberta B

AU - Edwards, Robert P

AU - Jensen, Allan

AU - Kjær, Susanne K

AU - Høgdall, Estrid

AU - Berchuck, Andrew

AU - Cramer, Daniel W

AU - Terry, Kathryn L

AU - Poole, Elizabeth M

AU - Bandera, Elisa V

AU - Paddock, Lisa E

AU - Anton-Culver, Hoda

AU - Ziogas, Argyrios

AU - Menon, Usha

AU - Gayther, Simon A

AU - Ramus, Susan J

AU - Gentry-Maharaj, Aleksandra

AU - Pearce, Celeste Leigh

AU - Wu, Anna H

AU - Pike, Malcolm C

AU - Webb, Penelope M

AU - Australian Ovarian Cancer Study Group

PY - 2017/4/25

Y1 - 2017/4/25

N2 - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

AB - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited.METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths).RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)).CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.

KW - Acetaminophen/therapeutic use

KW - Adult

KW - Aged

KW - Analgesics/therapeutic use

KW - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use

KW - Anticarcinogenic Agents/therapeutic use

KW - Aspirin/therapeutic use

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Middle Aged

KW - Ovarian Neoplasms/drug therapy

KW - Proportional Hazards Models

KW - Risk Factors

U2 - 10.1038/bjc.2017.68

DO - 10.1038/bjc.2017.68

M3 - Letter

C2 - 28350790

SN - 0007-0920

VL - 116

SP - 1223

EP - 1228

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

IS - 9

ER -